Which medication is indicated for the treatment of obesity in combination with bupropion?

The medication indicated for the treatment of obesity in combination with bupropion is the combination of phentermine and topiramate. This combination works synergistically to promote weight loss by suppressing appetite and enhancing metabolic rate. Phentermine acts primarily as an appetite suppressant through sympathetic stimulation, while topiramate contributes by affecting neurotransmitter systems related to appetite control and weight management.

In terms of weight management, when these two medications are combined, they effectively improve weight loss outcomes beyond what can be achieved with either medication alone. This combination has been shown to be effective in clinical trials for treating obesity, making it a suitable option for patients who require pharmacotherapy in addition to lifestyle changes.

Other options, despite having roles in managing various conditions, are not directly indicated or approved for use in conjunction with bupropion for obesity. For instance, topiramate is an anticonvulsant and can be used for prevention of migraines and management of epilepsy but is not specifically indicated for obesity treatment when used alone. Lisdexamfetamine is primarily indicated for ADHD and has limited application for weight loss. Fluoxetine, an SSRI antidepressant, is not indicated for obesity management in the context of this combination therapy. Thus, the pharmacological properties and approved indications